102212-26-0

Basic information

• Product Name: ARN-2966
• Synonyms: ARN-2966;2-PMAP;ARN2966(2-PMAP)
• CAS NO: 102212-26-0
• Molecular Formula: C₁₂H₁₂N₂O
• Molecular Weight: 200.23648
• Mol File: 102212-26-0.mol

Chemical Properties

• Melting Point: 130 °C(Solv: chloroform (67-66-3); hexane (110-54-3))
• Boiling Point: 354.4±27.0 °C(Predicted)
• Appearance: /
• Density: 1.241±0.06 g/cm3(Predicted)
• Solubility: Soluble in DMSO
• PKA: 10.22±0.35(Predicted)
• CAS DataBase Reference: ARN-2966(CAS DataBase Reference)
• NIST Chemistry Reference: ARN-2966(102212-26-0)
• EPA Substance Registry System: ARN-2966(102212-26-0)

Safety Data

• Hazardous Substances Data: 102212-26-0(Hazardous Substances Data)

Usage

Biological Activity

arn2966 is a potent post-transcriptional modulator of amyloid precursor protein (app) expression in transfected cho cells. the cho cell can produce app.[1]app is the amyloid precursor protein of alzheimer’s disease. alzheimer’s disease is a progressive dementia with the symptoms of neuronal degeneration, synaptic loss, and the deposition of amyloid fibrils in the brain. ab protein is the major constituent of the amyloid . then the ab protein derives from the amyloid precursor protein (app). it has been proved that app can stimulate neurite outgrowth in vitro. [2]the modulation of app expression of the arn2966 functions as a post-transcriptional modulation,which is different from other mechanisms such as inhibition of secretases. arn2966 showed dose dependant inhibition of a?40 and a?42 productions in app751sw transfected cho cells (ic50<1 mm for a?40), along with lowering the level of app and c83, and c99 peptides, while the level of app mrna was unaffected..[1]there has been ad transgenic mice model proved arn2966’s efficacy and tolerability in vivo. through the treatment of arn2966, the memory of mice has been improved and a load in the brain has been reduced.

references

[1] ayodeji asuni ,xu kevin , etal. , an app translation modulator arn2966 reduces beta-amyloid deposition and prevents memory deficits in alzheimer's disease transgenic mice. alzheimer's & dementia: the journal of the alzheimer's association, july 2012volume 8, issue 4, supplement, page s744 ;[2]williamson tg1, mok ss, henry a, etal. , secreted glypican binds to the amyloid precursor protein of alzheimer's disease (app) and inhibits app-induced neurite outgrowth. j biol chem. 1996 dec 6;271(49):31215-21.

Upstream product

• 3860-58-0 2-[(2-pyridinylmethylene)amino]phenol 
• 1121-60-4 pyridine-2-carbaldehyde 
• 95-55-6 2-amino-phenol 

Downstream Products

• 156214-73-2 2-(N,N-bis(2-methylpyridyl)aminomethyl)-6-(N-(2-hydroxyphenyl)-N-(2-pyridylmethyl)aminomethyl)-4-methylphenol 

Relevant articles and documents

PYRIDYL-2-METHYLAMINO COMPOUNDS, COMPOSITIONS AND USES THEREOF

Compounds are provided according to formula I: where R, R′, R3, R4, R5, and R6 are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a v

Synthesis, structural, magnetic, and redox properties of asymmetric diiron complexes with a single terminally bound phenolate ligand. Relevance to the purple acid phosphatase enzymes

New asymmetrical ligands (H2L) have been synthesized to provide both a bridging and a terminal phenolate to a pair of iron ions in order to mimic the binding of a single terminal tyrosinate at the diiron center of the purple acid phosphatases. H2L1 is 2-(bis(2-pyridylmethyl) amino)methyl]-6-[((2-pyridylmethyl)(2-phenol)amino)methyl] 4-methylphenol and H2L'1 and H2L2 are obtained by replacing the 2-phenol group by the 5-nitro-2-phenol and the 6-methyl-2-phenol residues, respectively. A series of mixed valence diiron complexes [Fe(II)Fe(III)L(X)2](Y) have been obtained where (X)2 is the dianion of m-phenylenedipropionate or (H2PO4)2 and Y = BPh4 or PF6 (L = L1, 1a (X)2 = mpdp, Y = BPh4, 1b: (X)2 = (OAc)2, Y = BPh4, 1c: (X)2 = (OBz)2, Y = BPh4, 1d: (X)2 = (H2PO4)2 Y = PF6; L = L'1: 1'a(X)2 mpdp, Y = BPh4; L = L2: 2c: (X)2 = (OBz)2, Y = BPh4, 2d: (X)2 (H2PO4)2, Y = PF6. Diferric complexes have been obtained also either by direct synthesis or by iodine oxidation of the mixed valence precursor (L = L1, 3a (X)2 = mpdp, Y = BPh4, 3d: (X)2 = (H2PO4)2, Y = PF6; L = L2, 4d: (X)2 = (H2PO4)2, Y = PF6. Complex 1a [Fe(II)Fe(III)L(mpdp)](BPh4)) has been characterized by X-ray diffraction techniques. 1a crystallizes in the monoclinic space group P21/a with the following unit cell parameters: a = 22.038 (9) ?, b = 16.195 (8) ?, c = 16.536 (7) ?, β = 97.26 (1)°, Z = 4. The significant differences in the Fe-O bond lengths indicate that the metal centers are ordered. The complexes have been studied by electronic spectral, resonance Raman, magnetic susceptibility, Mossbauer, NMR, and electrochemical techniques. Mossbauer and NMR spectroscopies concur to probe that the valences of the mixed valence compounds are trapped in solution as well as in the solid state at room temperature. The electronic spectrum of the mixed-valence compounds are dominated by a charge transfer transition in the 400-600 nm domain which moves to the 550-660 nm range upon oxidation to the diferric state. In addition they exhibit a weak and broad intervalence transition close to 1100 nm. Electrochemical studies show that the systems exist in the three redox states Fe(II)Fe(II)/Fe(II)Fe(III)/Fe(III)Fe(III). Moreover they show that the introduction of the terminal phenol group results in a thermodynamic destabilization of the diferrous state higher than the stabilization of the diferric state. An expanded stability domain of the mixed valence state is therefore observed which is probably due mostly to the asymmetry of the compounds. In addition a chemical destabilization of the reduced state of 1a, 1c, and 1'a is observed. Comparison of the carboxylate and phosphate derivatives leads to attribute it to the partial dissociation in solution of the carboxylate oxygen trans to the phenolate. The latter feature bears an intrinsic resemblance with the dissociation of iron which is observed when purple acid phosphatases are reduced by dithionite. These studies clearly show the importance of tyrosine binding on the redox properties of the PAP enzymes. This questions the relationship of such a redox specificity with a hydrolytic function and raises the possibility that the latter may be redox regulated or that another (redox based) function is actually involved, possibly in line with the ability of the enzymes to react with peroxides.

Esters and Lactones of Phenolic Amino Carboxylic Acids: Prodrugs for Iron Chelation

The new iron chelator N,N'-bis(2-hydroxyphenyl)ethylenediamine-N,N'-diacetic acid (1), its dilactone 2, N,N'-bis(2-hydroxybenzyl)-2-hydroxypropylene-1,3-diamine-N,N'-diacetic acid (3), and its methyl ester lactone 4 and a series of esters of N,N'-bis(2-hy